DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Spironolactone and Insulin Resistance in Chronic Heart Failure (CHF)

Information source: Tottori University Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Chronic Stable Heart Failure

Intervention: spironolactone + furosemide (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Tottori University Hospital

Summary

The purpose of this study is to evaluate the effects of spironolactone and furosemide on insulin resistance in patients with chronic heart failure.

Clinical Details

Official title: Effects of Spironolactone on Insulin Resistance in Patients With Chronic Heart Failure

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Primary outcome: insulin resistance

Detailed description: Diuretics is useful in CHF patients. On the other hand, they deteriorate glucose metabolism. Therefore, the purpose of this study is to evaluate the effects of spironolactone and furosemide on insulin resistance in patients with chronic heart failure.

Eligibility

Minimum age: N/A. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- chronic stable heart failure

Exclusion Criteria:

- renal dysfunction or under treatment with antidiabetic agents

Locations and Contacts

Additional Information

Starting date: January 2004
Last updated: April 21, 2008

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017